|
UBAP2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.81732406900892E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.57409640877404E-11 |
| Normal-vs-Stage2 |
1.46330000339034E-08 |
| Normal-vs-Stage3 |
2.00770511327164E-11 |
| Normal-vs-Stage4 |
1.64823710235851E-12 |
| Stage1-vs-Stage2 |
3.046200E-01 |
| Stage1-vs-Stage3 |
2.557600E-01 |
| Stage1-vs-Stage4 |
8.522000E-03 |
| Stage2-vs-Stage3 |
8.728000E-01 |
| Stage2-vs-Stage4 |
4.272600E-01 |
| Stage3-vs-Stage4 |
2.347600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.49333886870318E-12 |
| Normal-vs-AfricanAmerican |
3.634700E-04 |
| Normal-vs-Asian |
8.27549999971033E-07 |
| Caucasian-vs-AfricanAmerican |
9.233200E-01 |
| Caucasian-vs-Asian |
3.926600E-01 |
| AfricanAmerican-vs-Asian |
5.297400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.14330031289967E-10 |
| Normal-vs-Female |
1.7160717291631E-12 |
| Male-vs-Female |
3.435600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.89409998796464E-09 |
| Normal-vs-Age(41-60Yrs) |
1.72128977737884E-12 |
| Normal-vs-Age(61-80Yrs) |
8.48898729088887E-12 |
| Normal-vs-Age(81-100Yrs) |
1.61810999999012E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.254400E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.874100E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.849840E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.412200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.263600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
4.956400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
8.129600E-01 |
| Classical-VS-Follicular |
6.695600E-02 |
| Classical-VS-Other |
6.457200E-01 |
| Classical-VS-Normal |
3.06879965883411E-10 |
| Tall-VS-Follicular |
3.245200E-01 |
| Tall-VS-Other |
5.392600E-01 |
| Tall-VS-Normal |
3.26889999957558E-07 |
| Follicular-VS-Other |
3.321200E-01 |
| Follicular-VS-Normal |
1.56099577708346E-11 |
| Other-VS-Normal |
2.094100E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.93254351094674E-13 |
| Normal-vs-N1 |
9.36120003736107E-09 |
| N0-vs-N1 |
9.499200E-01 |
|
|
